Virtual Library
Start Your Search
T. Gonzaga
Author of
-
+
P3.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 208)
- Event: WCLC 2015
- Type: Poster
- Track: Treatment of Advanced Diseases - NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P3.01-034 - Long-Term Survival in Metastatic Non-Small Cell Lung Cancer: Predictive Clinical Factors (ID 330)
09:30 - 09:30 | Author(s): T. Gonzaga
- Abstract
Background:
While most patients with non-small cell lung cancer (NSCLC) stage IV, presents an unfavorable prognosis, a small proportion presents median overall survival beyond 2 years. The aim of this study is to identify clinical factors associated with long-term survival (LTS) in patients metastatic NSCLC.
Methods:
Single-center, retrospective study performed from the selection of patients in electronic medical records with a diagnosis of NSCLC, metastatic at diagnosis, and treated at AC Camargo Cancer Center in Brazil, from January / 2007 to June / 2014. We compared the group of patients who survived more than two years, the long-term survivors (LTS), to that survived less than two years, the short-term survival (STS), regarding the clinical characteristics and treatments performed. Using the chi-square test (categorical variable), and T test (continuous variables), for univariate analysis and by binary logistic regression model for multivariate analyzes, adopting the significance level P < 0.05
Results:
From 292 patients with stage IV NSCLC, there were 46 (15.7%) patients who survived beyond 2 years, and the remaining 246 patients who survived less than two years, we selected a control group of 46 patients. In the LTS group, the median overall survival (OS) was 39.7 months, and five-year-survival was 10.8%, while in the control group median OS was 9.2 months. In the univariate analysis related to clinical factors, the LTS was associated with female gender (P: 0.03); not smoking (P: 0.013); ≤ 2 metastatic sites (P: 0.02); ECOG of 0-1 (P: 0.01); absence of extra-thoracic metastasis (P: 0.001); absence of liver metastasis (P: 0.004) absence of bone metastasis (P: 0.001); absence of weight loss (P: 0.03); absence of decreased appetite (P: 0.001); and the presence of activating mutation in the EGFR gene (0.024). In univariate analysis regarding factors related to treatment, the LTS was associated with: two or more systemic treatment lines (P: 0.001); partial or complete response in first-line chemotherapy (p = 0.0001); use of tyrosine-kinase inhibitor (p = 0.0001); and maintenance chemotherapy (P: 0.012). In multivariate analysis of clinical factors, were considered long predictors of survival: two or fewer metastatic sites (OR: 7.1; P: 0.008) and ECOG 0-1 (OR: 12.2 P: 0.024). There was a trend for female gender (OR: 3.1 P: 0.057).
Conclusion:
We conclude that, in our sample, patients with stage IV NSCLC who have ECOG 0-1 and oligometastatic disease (≤ 2 sites) are more likely to long-term survival.
